Keywords
Cannabis
Development
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the possible risk factors, motives, influence and consequences on neuropsychiatric development due to the comorbid use of cannabis among young people today. Methods: National Library of Medicine (PubMed), Virtual Health Library (VHL) and Directory of Open Access Journals (DOAJ) were the databases used for the methodological approach of this study. The methodological approach through a qualitative approach and literature review character. The descriptors used were “schizophrenia”, “cannabis” and “development” using the Boolean operator “and”. Inclusion criteria were all original articles, published in English, Portuguese and Spanish. Results: Of the cases of suicide during adolescence are selected with suicide attempts as combinations of possible consequences of cannabis during adolescence, having: disorder, depression and anxiety as findings. Schizophrenia is the most prevalent comorbidity among the possible neuropsychological influences of cannabidiol. Final considerations: Thus, it is concluded that the use of adolescence currently has risks and is related to the influence of tetrahydrocannabinol (THC) on the endobinoid system.
References
BLAIR THIES M, et al. Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response. Schizophr Bull Open, 2020; sgaa014–sgaa014.
BIDZINSKI KK, et al. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. npj Schizophrenia 2022; 8(1):1–11.
CARDNO AG, et al. Psychotic‐Like Experiences in Adolescence Occurring in Combination or Isolation: Associations with Schizophrenia Risk Factors. Psychiatr res clin pract, 2021;3(2): 67–75.
GAYER-ANDERSON C, et al. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. Soc Psychiatry Psychiatr Epidemiol, 2020: 645–657.
GRECHUK K, et al. Cannabis, Schizophrenia Risk and Genetics: A Case Report of a Patient With Homozygous Valine Catechol-O-Methyltransferase Polymorphism. Cureus, 2021: e15740–e15740.
HAFNER H. Psychosis and cannabis. Archives of Clinical Psychiatry 2005: 32(2):53–67.
KARIS K, et al. Altered Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic Patients. Frontiers in Molecular Neuroscience, 2018: 11.
MANUAL DO MINISTÉRIO DE SAÚDE. 2020. Disponível em: https://aps.saude.gov.br/noticia/11997. Acessado em: 3 de abril de 2022.
MUZAFFAR A, et al. Clinical Investigation on the Impact of Cannabis Abuse on Thyroid Hormones and Associated Psychiatric Manifestations in the Male Population. Frontiers in Psychiatry, 2021: 12.
NEILL E, et al. Examining which factors influence age of onset in males and females with schizophrenia. Schizophr Res, 2020: 265–270.
OUANOUCHE EH, et al. Cannabis and schizophrenia: characterisation of a risk factor in a sample of Moroccan patients hospitalised for psychosis. Middle East Current Psychiatry, 2022; 29(1): 1–8.
RASMUSSEN JØ, et al. Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. BMC Psychiatry, 2021; 404–404.
RENTERO D, et al. Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use. Adicciones, 2021; 95–108.
RODRIGO C, et al. A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development. Substance Abuse Treatment, Prevention, and Policy, 2010: 5(1): 16.
TAO R, et al. Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl Psychiatry, 2020: 158–158.
UHER R, et al. A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry, 2014; 14(1): 344.
ZHORNITSKY S, et al. Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. Journal of Addiction, 2015; 2015: e843762.